Drug Trial Radar · NCT06957691
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jan 14, 2026
Primary completion
Aug 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Shehzad Basaria, M.D.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Astellas Pharma US, Inc.
- First posted
- May 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if fezolinetant can treat hot flashes (vasomotor symptoms) in men with prostate cancer undergoing androgen deprivation therapy. The main questions it aims to answer are: * Does fezolinetant improve the frequency and severity of hot flashes? * Does fezolinetant cause any harm to the liver? * Does fezolinetant improve quality of life, sleep quality, fatigue, mood, sexual function, and metabolic parameters? Researchers will compare how people respond to fezolinetant versus a placebo, which does not contain any active medicine. Participants will: * Take fezolinetant or a placebo every day for 4 weeks * Visit the clinic once every 2 weeks for checkups and tests * Keep a diary of the number of times and intensity that they experience hot flashes
Conditions
- Prostate Cancer
- Prostate Cancer (Adenocarcinoma)
- Prostate Cancer Metastatic Disease
- Prostate Cancer Recurrent
- Prostate Carcinoma
- Prostate Neoplasm
- Prostate Adenocarcinoma
- Prostate Cancer With Bone Metastasis
- Vasomotor Disturbance
- Vasomotor Symptoms
- Vasomotor Symptoms (VMS)
- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
- Vasomotor Symptoms; Hot Flashes
- Androgen Deprivation Therapy
- Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma
- Androgen-deprivation Therapy
- Hot Flashes
- Hot Flushes
- Hot Flushes and/or Sweats
Interventions
fezolinetant - reference formulationDrug
Daily oral administration of fezolinetant at a dose of 45 mg
PlaceboDrug
Daily oral administration of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in the Frequency of Vasomotor Symptoms Through Daily Hot Flash Diary from Baseline to 4 WeeksTime frame: From baseline to the end of treatment at 4 weeks.
- Hepatic safety, as assessed by measuring liver function testsTime frame: From baseline to the end of treatment at 4 weeks.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.